



11th November, 2021

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Corporate Relationship Department
M/s .BSE Ltd.
Dalal Street, Fort
Mumbai – 400 001.

The Manager – Listing
M/s.National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra(E), **MUMBAI – 400 051.**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2021 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. We are also updating the financial results on the website of the Company. Please find enclosed a copy of the same along with press release.

2. Declared second interim dividend of Rs.0.50 ps (fifty paise only) (25%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2021-22. The date for taking on record of its shareholders eligible for the purpose of payment of second interim dividend i.e., record date is fixed as **the 24th day of November, 2021.** The payment of said interim dividend will be paid from **1st December, 2021.**

3. Reconstituted the following Committees of the Board:

(I) Audit Committee

- (i) Sri G.S. Murthy, Independent Director
- (ii) Sri T. V. Rao, Independent Director
- (iii) Sri D. G. Prasad, Independent Director
- (iv) Dr. M.U.R. Naidu, Independent Director
- (v) Sri Sridhar Sankararaman, Non-Executive and Non-Independent Director

(II) Nomination and Remuneration Committee


- (i) Sri G.S. Murthy, Independent Director
- (ii) Dr. M.U.R. Naidu, Independent Director
- (iii) Sri Sridhar Sankararaman, Non-Executive and Non-Independent Director

Meeting commenced at 12.10 p.m. and concluded at 2.15 p.m.

This is for your information.

Thanking you

Yours faithfully,
For NATCO Pharma Limited


M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)

Encl: as above